News

Analysis of data from the pooled Tenaya and Lucerne studies showed the faricimab achieved greater anatomic improvements compared to aflibercept during the matched-dosing period.

Greater anatomic improvements (central subfield thickness reduction, proportion with absence of subretinal fluid and intraretinal fluid) were seen with faricimab versus aflibercept during the matched dosing period (week 4, week 8, and week 12).

Arun Singh, MD, discusses Retinoblastoma in 2023 and the advancements of tumor chemotherapy from his presentation at the Asia-Pacific Academy of Ophthalmology (APAO) 2023 conference.

Arun Singh, MD, discusses Retinoblastoma in 2023 and the advancements of tumor chemotherapy from his presentation at the Asia-Pacific Academy of Ophthalmology (APAO) 2023 conference.

Ophthalmologists should be aware of a patient’s prior history

Multiple attendees of this year's EnVision Summit share insights into what makes the EnVision Summit an enjoyable experience and a great place to learn.

The considerations for biosimilars in clinical practice are interesting and remain to be determined, according to George A. Williams, MD.

According to the company, the investigational, novel eye drop candidate was assigned a PDUFA goal date of October 22, 2023.

Multiple attendees of this year's EnVision Summit share insights into their presentations.

Sessions offer training in ophthalmic translational research, problem-based learning

Scientists from globally renowned top medical institutions, including the Cleveland Clinic Cole Eye Institute, University Hospitals Eye Institute, and Akron Children’s Hospital Vision Center, will present their latest research findings on major blinding disorders including children’s vision issues, age-related macular degeneration, and glaucoma.

In a presentation at the EnVision Summit 2023 in Puerto Rico, Sumayya Ahmad, MD, pointed out that for patients with lower Schirmer’s scores and corneal staining, PRK may be a good choice. If the dry eye can be treated preoperatively and the eye has no staining, surgeons can consider LASIK.

Surgeon notes there is no good solution for ending use of topical medications

Those attending the Asia-Pacific Academy of Ophthalmology congress In Kuala Lumpur can celebrate the reconvening of the congress after a 2-year hiatus by joining in the “We Are Back” Fundraising Run.

This marks the first, in-person APAO congress since the COVID-19 pandemic

Further research is needed before dietary nitrate intake can be recommended as a therapy for age-related macular degeneration, according to the study authors.

In addition to observation, laser-assisted vitreolysis and pars plana vitrectomy (PPV) are options, all of which deserve careful consideration.

Having the best tools available is of the utmost importance in the operating room (OR).

At the EnVision Summit Ophthalmology in Puerto Rico, Grace Sun, MD, made a presentation titled "Surgical Curriculum for Ophthalmology Residents" to train them to be competent in a broad range of basic and advanced surgical skills.

At the EnVision Summit Ophthalmology 2023 in Puerto Rico, Eva Kim, MD, made a presentation titled "ICL and Clear Lens Exchange: Choosing the Right Approach."

Corneal neurotization is an efficacious procedure to restore sensation to a neurotrophic cornea, involving the surgical transfer of sensory nerve fibers to the cornea.

During the EnVision Summit Ophthalmology in Puerto Rico, Victor Villegas, MD, made a presentation titled "From a Retina Perspective: Comanagement of AMD, DME and CME in the Setting of Cataract Surgery," focusing on how to comanage patients that have macular degeneration, diabetic maculopathy and cystoid macular edema.

David Huang, MD, PhD, is recognized as a co-creator of a widely used medical imaging technology.

Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD. This news follows the submission of the 24-month phase 3 data in November 2022.

Apellis has received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD. This news follows the submission of the 24-month phase 3 data in November 2022.

Apellis has received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD. This news follows the submission of the 24-month phase 3 data in November 2022.